A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”

Podobne knjige/članki

• A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”
  od: Sonja Ständer, et al.
  Izdano: (2025-12-01)
• Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’
  od: Mike Bastian, et al.
  Izdano: (2024-02-01)
• Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”
  od: Raj Chovatiya, et al.
  Izdano: (2025-12-01)
• Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
  od: Kim Rand, et al.
  Izdano: (2023-10-01)
• Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison
  od: Surya P. Bhatt, et al.
  Izdano: (2025-09-01)